MedPath

A Study Of Paachana Modality In The Patients Of Dyslipidaemia

Phase 1
Not yet recruiting
Conditions
Hyperlipidemia, unspecified,
Registration Number
CTRI/2020/04/024513
Lead Sponsor
ALL INDIA INSTITUTE OF AYURVEDA
Brief Summary

Amongst the Shat Upakarma as explained by Acharya Charaka one is Langhana therapy. Here the word Langhana means Laghu that is the whole procedure of producing lightness in the body at various level like Dosha, Dhatu, Mala or even at Manas i.e. at psychological level. 10 types of Langhana are described by Acharya Charaka in Sutrasthana, one among them is Pachana or it can be understood as Shamana rupi langhana. It is the treatment principle which is adopted for the digestion of Ama Sansrishtha conditions at various entities i.e. Koshtha, Dosha, Dhatu etc.  Furthermore, Autophagy is a normal physiological process in the body that deals with destruction of cells within the body. It maintains homeostasis or normal functioning by protein or Fat degradation. Autophagy mainly maintains a balance between manufacture of cellular components and break down of damaged or unnecessary organelles and other cellular constituents. Autophagy also removes and clears damaged cell organelles. It is the natural, regulated mechanism of the cell that disassembles unnecessary or dysfunctional components. In and all it allows the orderly degradation and recycling of cellular components.4 This mechanism of autophagy can be understood more likely be the same what Pachana Karma performs in our body. Thus, Autophagy may be correlated with Pachana Karma. Pachana karma is indicated in Madhyam Bala Rogas i.e. the diseases with moderate strength or when Doshas are moderately vitiated, or in case of Kapha Pitta Samuttha Vyadhis, and hence, it can be used in Medo Dushti janita Vyadhis viz. Dyslipidaemia. Dyslipidaemia is a disorder of lipoprotein metabolism, which can include overproduction or deficiency of lipoproteins or both. The disorder can manifest as an elevation of plasma cholesterol, triglycerides, or both, or a low high-density lipoprotein level or all three together that contributes to the development of atherosclerosis. World Health Organization (WHO) in 2002 reported that high cholesterol level is one of the main non-communicable disease related risk factor in India. The Indian Council of Medical Research (ICMR) surveillance project reported a prevalence of Dyslipidaemia of 37.5% among adults, with an even higher prevalence of dyslipidaemia (62%) among young male industrial workers.  In Dyslipidaemia, there exists the condition of Ama and in Ayurveda the best line of treatment indicated for Ama is Langhana Karma one if its modality is Pachana Karma where we facilitate the digestion of undigested matter and thus this disease can be overcome by the process of Autophagy that may be considered to be generated through Paachana Karma.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Total Cholesterol (201-300 mg/dl) Serum TGLs (161mg/dl or more) Serum HDL (below 40mg/dl) Serum LDL (131mg/dl or more) Serum VLDL (41mg/dl or more).

Exclusion Criteria
  • Patients Who Are Under Conventional Medications.
  • Subjects With Diabetes.
  • Patients With Grave Disease, Psychological Disorders.
  • Patients With Hypothyroidism And Other Metabolic Disorders.
  • Patients With Cardio Vascular Diseases Like Hypertension And Other Severe Conditions.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total Cholesterol Less Then 200mg/dl Along With The Assessment Of Samyaka Of Lakshana Of Langhana60 days
Secondary Outcome Measures
NameTimeMethod
To Improve The Quality Of Life60 days

Trial Locations

Locations (1)

All India Institute Of Ayurveda

🇮🇳

Delhi, DELHI, India

All India Institute Of Ayurveda
🇮🇳Delhi, DELHI, India
Prof Dr Mahesh K Vyas
Principal investigator
8849802005
drmaheshkvyas@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.